We found that ELF4 vary between cancer types, for example, brain lower-grade gliomas (99.9% of the tumours) and prostate adenocarcinomas (99.6%) tended to express lower ELF4 levels, whereas acute myeloid leukaemias (92.7%) and oesophageal adenocarcinomas (92.8%) tended to express higher levels of ELF4 (Fig 2B). The gene discussed is ELF4; the disease is cancer.